



RECEIVED
1645
MAR 12 2002
TECH CENTER 500/2900

Please type a plus sign (+) inside this box →



Approved for use through 10/31/93 OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number Of Pages In This Submission

7 PAGES PLUS
47
REFERENCES

Application Number 09/925,720

Filing Date August 8, 2001

First Named Inventor Vincent GIGUERE

Group Art Unit 1645

Examiner Name To Be Assigned

Attorney Docket No. 514012000200

ENCLOSURES (check all that apply)

- | | | |
|---|--|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers
(for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment / Reply | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declarations | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | * PTO 1449 Form (3 pages) |
| <input checked="" type="checkbox"/> Information Disclosure Statement - 3 pages | <input type="checkbox"/> Request for Refund | * 47 References |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | * Return receipt postcard |
| <input type="checkbox"/> Response to Missing Parts/
Incomplete Application | Remarks | |
| <input type="checkbox"/> Response to Missing Parts
under 37 CFR 1.52 or 1.53 | | |

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name Gladys H. Monroy
Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, CA 94304

Signature

Gladys Monroy

Date

February 25, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on February 25, 2002.

Denise Lade
Denise Lade

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

pa-669571



Docket No. 514012000200

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on February 25, 2002.

Denise Lade

Denise Lade

RECEIVED
MAR 12 2002
TECHNICAL CENTER
PATENT & TRADEMARK OFFICE
JCS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Vincent GIGUERE et al.

Application No.: 09/925,720

Filing Date: August 08, 2001

For: NON-HUMAN TRANSGENIC ANIMAL
WHOSE GERM CELLS AND SOMATIC
CELLS CONTAIN A KNOCKOUT
MUTATION IN DNA ENCODING
ORPHAN NUCLEAR RECEPTOR
ERRALPHA

Examiner: To Be Assigned

Group Art Unit: 1645

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of _____ is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of _____ is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.


In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 514012000200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 25, 2002

Respectfully submitted,

By: Gladys H. Monroy
Gladys H. Monroy
Registration No. 32,430

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5711
Facsimile: (650) 494-0792



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 514012000200

Application Number 09/925,720

Applicant

Vincent GIGUERE et al.

Filing Date August 8, 2001

Group Art Unit 1645

Mailing Date February 25, 2002

TECH CENTER 1600/2900

MAR 12 2002

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	07/28/1987	4,683,195	Mullis et al.			
	2.	07/28/1987	4,683,202	Mullis			
	3.	01/24/1989	4,800,159	Mullis et al.			
	4.	10/23/1990	4,965,188	Mullis et al.			
	5.	03/29/1994	5,298,429	Evans et al.			
	6.	01/14/1997	5,593,974	Rosenberg et al.			
	7.	08/04/1998	5,789,654	Lowell et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	8.	05/13/1993	WO 93/08845	WIPO			
	9.	09/25/1996	EP 0 733 705 A1	Europe			
	10.	04/18/1996	WO 96/11266 A2, A3	WIPO			
	11.	10/24/1996	WO 96/32966 A1	WIPO			
	12.	04/01/1999	WO 99/15646	WIPO			
	13.	12/19/1996	WO 96/41169	WIPO			
	14.	08/17/2000	WO 00/47735 A2, A3	WIPO			
	15.	12/23/1999	WO 99 65486 A1	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	16.	Ausubel, F. M. et al. (1994). "Current Protocols in Molecular Biology," John Wiley & Sons, New York (Table of Contents) 13 pages total.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION REGARDING CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 514012000200

Application Number 09725,720

Applicant

Vincent GIGUERE et al.

Filing Date August 8, 2001

Group Art Unit 1645

Mailing Date February 25, 2002

RECEIVED
MAR 1 2 2002
TECH CENTER 1600/2500


RECEIVED

- | | |
|-----|--|
| 17. | Bryant, H. U. and Dere, W. H. (January 1998). "Selective Estrogen Receptor Modulators: Alternative to Hormone Replacement Therapy," <i>Proc. Soc. Exp. Biol. Med.</i> 217:45-52. |
| 18. | Escriva, H. et al. (June 1997). "Ligand Binding was Acquired During Evolution of Nuclear Receptors," <i>Proc. Natl. Acad. Sci.</i> 94:6803-6808. |
| 19. | Giguère, V. et al. (January 1988) "Identification of a New Class of Steroid Hormone Receptors," <i>Nature</i> 331:91-94. |
| 20. | Hanks, M. et al. (August 1995). "Rescue of the <i>En-1</i> Mutant Phenotype by Replacement of <i>En-1</i> with <i>En-2</i> ," <i>Science</i> 269:679-682. |
| 21. | Innis, M.A. (1990). "PCR Protocols, A Guide to Methods and Applications," (Table of Contents): Total Pages 7. |
| 22. | Johnston, S. D. et al. (1997). "Estrogen -Related Receptor $\alpha 1$ Functionally Binds as a Monomer to Extended Half-Site Sequences Including Ones Contained within Estrogen-Response Elements," <i>Mol. Endo.</i> 11(3):342-352 |
| 23. | Kwoh, D.Y. et al. (February 1989). "Transcription-Based Amplification System and Detection of Amplified Human Immunodeficiency Virus Type 1 with a Bead-Based Sandwich Hybridization Format," <i>Proc. Natl. Acad. Sci.</i> 86:1173-1177. |
| 24. | Kwoh, D.Y. and Kwoh, T. J. (October 1990). "Target Amplification System in Nucleic Acid-Based Diagnostic Approaches," <i>Am. Biotechnol. Lab</i> 8:14,16,18,20,and 21-25. |
| 25. | Lizardi, P.M. et al. (October 1988). "Research Papers/ Exponential Amplification of Recombinant-RNA Hybridization Probes," <i>Bio/Technology</i> 6:1197-1202. |
| 26. | Lowell, B.B. et al. (December 1993). "Development of Obesity in Transgenic Mice After Genetic Ablation of Brown Adipose Tissue," <i>Nature</i> 366(23):740-742. |
| 27. | Luo, J et al. (August 1997). "Placental Abnormalities in Mouse Embryos Lacking The Orphan Nuclear Receptor ERR- β ," <i>Nature</i> 388:778-782. |
| 28. | Malek, L. et al. (1994). "Nucleic Acid Sequence-Based Amplification (NASB TM)" Chapter 36 <i>In Methods in Molecular Biology: Protocols for Nucleic Acid Analysis by Nonradioactive Probes</i> . P.G. Isaac ed., Humana Press Inc, Totowa, NJ, 28:253-261. |
| 29. | Miller, P.S. et al. (1988). "Oligonucleotide Inhibitors of Gene Expression in Living Cells: New Opportunities in Drug Design" Chapter 30 <i>In Annual Reports in Medical Chemistry</i> . Vinick, ed., Academic Press Inc., 23:295-304. |
| 30. | Morvan, F. et al. (May 1986). " α -DNA I. Synthesis, Characterization by High Field ¹ H-NMR, and Base-Pairing Properties of the Unnatural Hexadeoxyribonucleotide α -[d(CpCpTpTpCpC)] with its Complement β -[d(GpGpApApGpG)]," <i>Nucleic Acid Molecule Acids Res.</i> 14(12):5019-5035. |
| 31. | Nagy, A. and Rossant, J. (1993) "Production of Completely ES Cell-Derived Fetuses," <i>In Gene Targeting: A Practical Approach</i> , A.L. Joyner ed. Oxford University Press, pp.147-169 |
| 32. | Osol, A. (1980). "Remington's Pharmaceutical Sciences," 16th Ed., Mack Publishing Company (Table of Contents) total pages 3. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 514012000200	Application Number 09/025,729
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Vincent GIGUERE et al.	
		Filing Date August 8, 2001	Group Art Unit 1645
		Mailing Date February 25, 2002	
		Petterson, K. et al. (1996). "Expression of a Novel Member of Estrogen Response Element-Binding Nuclear Receptors is Restricted to the Early Stages of Chorion Formation During Mouse Embryogenesis," <i>Mech of Dev.</i> 54:211-223.	
34.	Sambrook, J. et al. (1989) "Molecular Cloning- A Laboratory Manual," Cold Spring Harbor Laboratory Press, (Table of Contents) pgs xi-xxxviii.		
35.	Sladek, R. et al. (August 1997). "Chromosomal Mapping of the Human and Murine Orphan Receptors ERR α (ESRRA) and ERR β (ESRRB) and Identification of a Novel Human ERR α -Related Pseudogene," <i>Genomics</i> 45(GE97493):320-326.		
36.	Sladek, R. et al. (September 1997). "The Orphan Nuclear Receptor Estrogen-Related Receptor α Is a Transcriptional Regulator of the Human Medium-Chain Acyl Coenzyme A Dehydrogenase Gene," <i>Mol. and Cell. Biol.</i> 17(9):5400-5409.		
37.	Tybulewicz, V. L. J. et al. (June 1991). "Neonatal Lethality and Lymphopenia in Mice with a Homozygous Disruption of the <i>c-abl</i> Proto-Oncogene," <i>Cell</i> 65:1153-1163.		
38.	Vanacker, J. et al. (1998). "Activation of the Thyroid Hormone Receptor α Gene Promoter by the Orphan Nuclear Receptor ERR α ," <i>Oncogene</i> 17:2429-2435.		
39.	Vega, R. and Kelly, D. P. (December 1997). "A Role for Estrogen-Related Receptor α in the Control of Mitochondrial Fatty Acid β -Oxidation during Brown Adipocyte Differentiation," <i>The J. of Biol. Chem.</i> 272(50):31693-31699.		
40.	Walker, G.T. et al. (January 1992). "Isothermal <i>In Vitro</i> Amplification of DNA by a Restriction Enzyme/DNA Polymerase System," <i>Proc. Natl. Acad. Sci.</i> 89:392-396.		
41.	Walker, G.T. et al. (March 1992). "Strand Displacement Amplification-an Isothermal, <i>In Vitro</i> DNA Amplification Technique," <i>Nucleic Acids Res.</i> 20(7):1691-1696.		
42.	Weiss, R. (November 1991). "Hot Prospect for New Gene Amplifier: Ligase Chain Reaction, A Combination DNA Amplifier and Genetic Screen, Could Do for DNA Diagnostics What PCR has Done for Basic Molecular Biology," <i>Science</i> 254:1292-1293.		
43.	Yang, N. et al. (March 1996). "Estrogen-Related Receptor, hERR1, Modulates Estrogen Receptor-Mediated Response of Human Lactoferrin Gene Promoter," <i>The J. of Biol. Chem.</i> 271(10):5795-5804.		
44.	Yang, C. et al. (December 1998). "Modulation of Aromatase Expression in the Breast Tissue ERR α -1 Orphan Receptor ¹ ," <i>Cancer Res.</i> 58:5695-5700.		
45.	Yasruel, Z. et al. (April 1991). "Effect of Acylation Stimulating Protein on the Triacylglycerol Synthetic Pathway of Human Adipose Tissue," <i>Lipids</i> 26(7):495-499		
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			